Sumitomo Mitsui Trust Group Inc. Acquires 262,347 Shares of Arcturus Therapeutics Holdings Inc. $ARCT

Sumitomo Mitsui Trust Group Inc. boosted its holdings in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 12.9% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,288,935 shares of the biotechnology company’s stock after purchasing an additional 262,347 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned about 0.08% of Arcturus Therapeutics worth $17,671,000 as of its most recent SEC filing.

Several other institutional investors have also bought and sold shares of ARCT. Osaic Holdings Inc. grew its stake in shares of Arcturus Therapeutics by 51.8% in the 2nd quarter. Osaic Holdings Inc. now owns 2,163 shares of the biotechnology company’s stock worth $28,000 after buying an additional 738 shares in the last quarter. CANADA LIFE ASSURANCE Co raised its position in shares of Arcturus Therapeutics by 27.5% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 7,272 shares of the biotechnology company’s stock valued at $136,000 after buying an additional 1,567 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Arcturus Therapeutics by 0.7% in the 2nd quarter. Bank of America Corp DE now owns 292,429 shares of the biotechnology company’s stock valued at $3,805,000 after acquiring an additional 2,098 shares during the last quarter. BNP Paribas Financial Markets lifted its holdings in shares of Arcturus Therapeutics by 163.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,169 shares of the biotechnology company’s stock valued at $54,000 after acquiring an additional 2,586 shares during the last quarter. Finally, Two Sigma Investments LP grew its position in Arcturus Therapeutics by 3.3% in the third quarter. Two Sigma Investments LP now owns 89,219 shares of the biotechnology company’s stock worth $1,644,000 after acquiring an additional 2,857 shares in the last quarter. Institutional investors own 94.54% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently issued reports on ARCT. B. Riley Financial started coverage on Arcturus Therapeutics in a research note on Wednesday, March 18th. They issued a “buy” rating and a $22.00 price objective for the company. Weiss Ratings raised Arcturus Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Arcturus Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $24.25.

Arcturus Therapeutics Price Performance

Shares of NASDAQ ARCT opened at $6.71 on Tuesday. The company has a market cap of $190.70 million, a P/E ratio of -2.39 and a beta of 2.37. Arcturus Therapeutics Holdings Inc. has a 1 year low of $5.85 and a 1 year high of $24.17. The firm has a 50-day simple moving average of $7.44 and a two-hundred day simple moving average of $7.48.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its earnings results on Friday, May 8th. The biotechnology company reported ($0.95) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.03) by $0.08. Arcturus Therapeutics had a negative return on equity of 36.55% and a negative net margin of 143.80%.The business had revenue of $2.06 million during the quarter, compared to analyst estimates of $6.30 million. As a group, equities research analysts expect that Arcturus Therapeutics Holdings Inc. will post -3.99 EPS for the current year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.